TISIDB

Summary
Symbol	AXL
Name	AXL receptor tyrosine kinase
Aliases	UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location	19q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein
Domain	PF00041 Fibronectin type III domain PF07714 Protein tyrosine kinase
Function	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of AXL. Following activation by ligand, ALX binds and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory subunits by AXL leads to the downstream activation of the AKT kinase. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response. ; FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and lymphocytic choriomeningitis virus, possibly through GAS6 binding to phosphatidyl-serine at the surface of virion envelope. ; FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus, possibly through GAS6 binding to phosphatidyl-serine at the surface of virion envelope.

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0001764 neuron migration GO:0001779 natural killer cell differentiation GO:0001818 negative regulation of cytokine production GO:0001959 regulation of cytokine-mediated signaling pathway GO:0001961 positive regulation of cytokine-mediated signaling pathway GO:0001974 blood vessel remodeling GO:0002237 response to molecule of bacterial origin GO:0002262 myeloid cell homeostasis GO:0002521 leukocyte differentiation GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002695 negative regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0006907 pinocytosis GO:0006909 phagocytosis GO:0006979 response to oxidative stress GO:0007283 spermatogenesis GO:0007548 sex differentiation GO:0007596 blood coagulation GO:0007599 hemostasis GO:0009991 response to extracellular stimulus GO:0010035 response to inorganic substance GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0019058 viral life cycle GO:0021700 developmental maturation GO:0021885 forebrain cell migration GO:0030098 lymphocyte differentiation GO:0030100 regulation of endocytosis GO:0030101 natural killer cell activation GO:0030168 platelet activation GO:0030260 entry into host cell GO:0030540 female genitalia development GO:0030900 forebrain development GO:0031099 regeneration GO:0031100 animal organ regeneration GO:0031589 cell-substrate adhesion GO:0031668 cellular response to extracellular stimulus GO:0032496 response to lipopolysaccharide GO:0032609 interferon-gamma production GO:0032640 tumor necrosis factor production GO:0032649 regulation of interferon-gamma production GO:0032680 regulation of tumor necrosis factor production GO:0032689 negative regulation of interferon-gamma production GO:0032720 negative regulation of tumor necrosis factor production GO:0032814 regulation of natural killer cell activation GO:0032816 positive regulation of natural killer cell activation GO:0032823 regulation of natural killer cell differentiation GO:0032825 positive regulation of natural killer cell differentiation GO:0034101 erythrocyte homeostasis GO:0034446 substrate adhesion-dependent cell spreading GO:0034599 cellular response to oxidative stress GO:0034614 cellular response to reactive oxygen species GO:0035455 response to interferon-alpha GO:0035457 cellular response to interferon-alpha GO:0042542 response to hydrogen peroxide GO:0042698 ovulation cycle GO:0043277 apoptotic cell clearance GO:0043491 protein kinase B signaling GO:0043523 regulation of neuron apoptotic process GO:0043524 negative regulation of neuron apoptotic process GO:0044409 entry into host GO:0045619 regulation of lymphocyte differentiation GO:0045621 positive regulation of lymphocyte differentiation GO:0045807 positive regulation of endocytosis GO:0046660 female sex differentiation GO:0046718 viral entry into host cell GO:0048010 vascular endothelial growth factor receptor signaling pathway GO:0048232 male gamete generation GO:0048469 cell maturation GO:0048511 rhythmic process GO:0048548 regulation of pinocytosis GO:0048549 positive regulation of pinocytosis GO:0048608 reproductive structure development GO:0048771 tissue remodeling GO:0048806 genitalia development GO:0048872 homeostasis of number of cells GO:0050817 coagulation GO:0050865 regulation of cell activation GO:0050866 negative regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050878 regulation of body fluid levels GO:0051249 regulation of lymphocyte activation GO:0051250 negative regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051402 neuron apoptotic process GO:0051701 interaction with host GO:0051806 entry into cell of other organism involved in symbiotic interaction GO:0051828 entry into other organism involved in symbiotic interaction GO:0051896 regulation of protein kinase B signaling GO:0051897 positive regulation of protein kinase B signaling GO:0060068 vagina development GO:0060627 regulation of vesicle-mediated transport GO:0060759 regulation of response to cytokine stimulus GO:0060760 positive regulation of response to cytokine stimulus GO:0061458 reproductive system development GO:0070301 cellular response to hydrogen peroxide GO:0070997 neuron death GO:0071216 cellular response to biotic stimulus GO:0071219 cellular response to molecule of bacterial origin GO:0071222 cellular response to lipopolysaccharide GO:0071396 cellular response to lipid GO:0071496 cellular response to external stimulus GO:0071706 tumor necrosis factor superfamily cytokine production GO:0071887 leukocyte apoptotic process GO:0097028 dendritic cell differentiation GO:0097048 dendritic cell apoptotic process GO:1901214 regulation of neuron death GO:1901215 negative regulation of neuron death GO:1902105 regulation of leukocyte differentiation GO:1902107 positive regulation of leukocyte differentiation GO:1903555 regulation of tumor necrosis factor superfamily cytokine production GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:2000106 regulation of leukocyte apoptotic process GO:2000107 negative regulation of leukocyte apoptotic process GO:2000668 regulation of dendritic cell apoptotic process GO:2000669 negative regulation of dendritic cell apoptotic process
Molecular Function	GO:0001618 virus receptor activity GO:0001786 phosphatidylserine binding GO:0004713 protein tyrosine kinase activity GO:0004714 transmembrane receptor protein tyrosine kinase activity GO:0005543 phospholipid binding GO:0017022 myosin binding GO:0019199 transmembrane receptor protein kinase activity GO:0032036 myosin heavy chain binding GO:0043548 phosphatidylinositol 3-kinase binding GO:0046982 protein heterodimerization activity GO:0072341 modified amino acid binding
Cellular Component	GO:0018995 host GO:0033643 host cell part GO:0043657 host cell GO:0044215 other organism GO:0044216 other organism cell GO:0044217 other organism part GO:0044228 host cell surface

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-162582: Signal Transduction R-HSA-194138: Signaling by VEGF R-HSA-4420097: VEGFA-VEGFR2 Pathway

Summary
Symbol	AXL
Name	AXL receptor tyrosine kinase
Aliases	UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location	19q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between AXL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	AXL
Name	AXL receptor tyrosine kinase
Aliases	UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location	19q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of AXL in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	AXL
Name	AXL receptor tyrosine kinase
Aliases	UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location	19q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of AXL in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.391	0.00354
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.79	0.27
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.098	0.368
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.201	0.658
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.03	0.99
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.416	0.897
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.236	0.678
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.328	0.823
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.081	0.962
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.686	0.338
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.108	0.419
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.369	0.00844

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of AXL in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	6.8	0.6	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	8.5	-1.1	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	0	14.3	0.238
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	6.2	16	0.53
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	11.1	8.9	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	AXL
Name	AXL receptor tyrosine kinase
Aliases	UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location	19q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AXL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	AXL
Name	AXL receptor tyrosine kinase
Aliases	UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location	19q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AXL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AXL. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	AXL
Name	AXL receptor tyrosine kinase
Aliases	UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location	19q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AXL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	AXL
Name	AXL receptor tyrosine kinase
Aliases	UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location	19q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of AXL expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	AXL
Name	AXL receptor tyrosine kinase
Aliases	UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location	19q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between AXL and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	AXL
Name	AXL receptor tyrosine kinase
Aliases	UFO; JTK11; Tyro7; AXL oncogene; AXL transforming sequence/gene; Tyrosine-protein kinase receptor UFO
Chromosomal Location	19q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting AXL collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse AXL